FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.
Conclusions: IO patients showed significant benefit in OS with HRs comparable to those reported in phase III trials. The benefit tended to be greater in patients with lower tumor mass.Oncology
First major improvements in NSCLC care have been achieved by the identification of targetable oncogenic alterations together with specific targeted therapies. However, the vast majority of Caucasian lung cancer patients do not present with a targetable driver mutation and standard cytotoxic chemotherapy (ChT) and anti-angiogenic strategies represented the cornerstones of systemic lung cancer treatment for decades. Nowadays, the treatment of advanced Non-Small-Cell Lung Cancer (NSCLC) is radically transforming.
Authors: Debieuvre D, Moreau L, Coudert M, Locher C, Asselain B, Coëtmeur D, Dayen C, Goupil F, Martin F, Brun P, De Faverges G, Hauss PA, Gally S, Ben Hadj Yahia B, Grivaux M Abstract INTRODUCTION: The benefit of tyrosine kinase inhibitors for patients with an EGFR wild-type non-small cell lung cancer (NSCLC) remains controversial. METHODS: The survival of patients with an EGFR wild-type NSCLC who received second- or third-line erlotinib treatment was assessed using real-life data that had been collected in a prospective, national, multicenter, non-interventional cohort study. RESULTS: Data from 274 p...
Authors: Rouviere D, Veillon R, Chaltiel L, Simonneau Y, Filleron T, Milia J, Guibert N, Melloni B, Raherisson C, Didier A, Mazieres J Abstract The central nervous system (CNS), through carcinomatous meningitis or solid brain metastases, is the most common site of recurrence in non-small cell lung cancers (NSCLC) with activating mutations. Our retrospective study describes the population of patients with CNS metastases of NSCLC harboring activating mutation with targeted therapy (EGFR, ALK, BRAF, HER2) in 4 French regional reference hospitals. 60 patients were analyzed. The proposed treatments were heterogeneous an...
CONCLUSIONS: Exercise training increased exercise capacity and quadriceps muscle force of people following lung resection for NSCLC. Our findings also suggest improvements on the physical component score of general HRQoL and decreased dyspnoea. This systematic review emphasises the importance of exercise training as part of the postoperative management of people with NSCLC. PMID: 31204439 [PubMed - as supplied by publisher]
Cytotoxic chemotherapy remains an important treatment for patients with non-small cell lung cancer (NSCLC) either alone or in combination with immunotherapy. Studies demonstrating the efficacy of first line treatment with immune checkpoint inhibitors (ICI) alone and in combination with chemotherapy have led to new first-line treatment options for patients with NSCLC [1 –3]. Carboplatin, pembrolizumab and either paclitaxel or nab-paclitaxel are now standard first line options for patients with lung squamous cell carcinoma (LSCC) .
AbstractPurposeBased on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive value of pemetrexed sensitivity to outcomes of subsequent systemic treatment was investigated.MethodsWe retrospectively reviewed the patients with metastatic non-squamous NSCLC treated with pemetrexed monotherapy as their first- or second-line chemotherapy between November 2006 and February 2015. Good (top 5% longest) and poor responders (bottom 12% shortest) were defined according to the duration of pemetrexed maintenance. The first and second post-pemetrexed (PP) systemic treatments were...
There has been no recent randomized evidence justifying postoperative radiation therapy (PORT) in patients with non-small cell lung cancer who have undergone complete resection; it is not recommended for routine use, even in patients with mediastinal involvement (pN2).1,2 Adjuvant treatments such as chemotherapy and PORT should be discussed at a multidisciplinary board with complete surgical and pathologic reports, checking whether the nodal exploration was appropriate, the location and number of mediastinal nodes and hilar/intrapulmonary nodes that were resected, and whether resection was complete.
Condition: NSCLC Interventions: Drug: Kanglaite Injection+Chemotherapy; Drug: Chemotherapy Sponsors: Jie Li; Ministry of Science and Technology of the People´s Republic of China; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Not yet recruiting
This article reviewed the predictive value of TMB and its limitations in the field of immunotherapy for lung cancer. DOI: 10.3779/j.issn.1009-3419.2019.06.08